Compare YDDL & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YDDL | NTHI |
|---|---|---|
| Founded | 2014 | 2008 |
| Country | Philippines | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 104.8M | 121.3M |
| IPO Year | 2024 | 2023 |
| Metric | YDDL | NTHI |
|---|---|---|
| Price | $1.69 | $4.79 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | ★ 520.6K | 263.4K |
| Earning Date | 04-27-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $39,990.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $40.85 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.61 | $3.01 |
| 52 Week High | $16.23 | $12.99 |
| Indicator | YDDL | NTHI |
|---|---|---|
| Relative Strength Index (RSI) | 47.10 | 57.11 |
| Support Level | $1.75 | $4.18 |
| Resistance Level | $1.94 | $5.79 |
| Average True Range (ATR) | 0.15 | 0.55 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 15.69 | 52.08 |
One and one Green Technologies Inc is engaged in recycling, production, and trading of recycled scrap metals in the Republic of the Philippines. The company processes raw materials and generates final products that include copper alloy ingots, aluminum scrapes, plastic beads, and others. It provides economical and flexible solutions to the challenges of electronic waste, metal scrap, and industrial recycling. The company operates and manages its business as a single segment and has one operating and reportable segment, trading of recycled scrap metals. Geographically, it generates the majority of its revenue from China.
NeOnc Technologies Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel molecular technologies for the targeted delivery of therapeutics to treat central nervous system diseases. The company is developing drug delivery methods and drug candidates for intracranial malignancies such as gliomas, glioblastoma, and meningioma. Its lead product candidates include NEO100, an intranasal drug delivery therapy for brain cancer patients, and NEO212, an oral chemical conjugate designed to enhance treatment for glioblastoma.